DailySand tracks Zealand across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where Zealand appears in today's cross-sector intelligence briefing.
1 item across 1 digest
Zealand's stock plummeted 35% after their joint drug with Roche showed disappointing 10.7% weight loss results in mid-stage trials. CEO downplays competitive comparisons amid intense competition in the weight-loss drug market.
Read original →
DailySand